Implementing the EffTox dose-finding design in the Matchpoint trial

BMC Medical Research Methodology

Volumn 17, Issue 1, 2017, Pages

  Brock, Kristian ^a   Billingham, Lucinda ^a   Copland, Mhairi ^b   Siddique, Shamyla ^a   Sirovica, Mirjana ^a   Yap, Christina ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CML; Dose finding; Efficacy; EffTox; Phase I II; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; FLUDARABINE; IDARUBICIN; IMIDAZOLE DERIVATIVE; PONATINIB; PYRIDAZINE DERIVATIVE; VIDARABINE;

ALGORITHM; ANALOGS AND DERIVATIVES; BAYES THEOREM; BLAST CELL CRISIS; CLINICAL TRIAL; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BLAST CRISIS; CYTARABINE; HUMANS; IDARUBICIN; IMIDAZOLES; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PYRIDAZINES; RESEARCH DESIGN; VIDARABINE;

EID: 85025069055     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-017-0381-x     Document Type: Article

References (35)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med. 2006; 355(23):2408-17.
2. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4):494-501. doi: 10.1182/blood-2013-06-511592.
3. Larson R, Hochhaus A, Hughes T, Clark R, Etienne G, Kim DW, Flinn I, Kurokawa M, Moiraghi B, Yu R, Blakesley R, Gallagher N, Saglio G, Kantarjian H. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up This article has been corrected since Advance Online Publication and a corrigendum is also printed. Leukemia. 2012; 26:2197-203. doi: 10.1038/leu.2012.134.
4. Hehlmann R. How I treat CML blast crisis How I treat How I treat CML blast crisis. Blood. 2012; 120(4):737-48. doi: 10.1182/blood-2012-03-380147.
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-42.
6. Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase,. Leukemia. 2012; 26(5):959-62. doi: 10.1038/leu.2011.355.
7. Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica. 2008; 93(12):1792-6. doi: 10.3324/haematol.13068.
8. Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010; 116(16):3852-61. doi: 10.1002/cncr.25123.
9. Jain N, Van Besien K. Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era. Hematol Oncol Clin N Am. 2011; 25(5):1025-48. doi: 10.1016/j.hoc.2011.09.003.
10. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006; 12(24):7374-9. doi: 10.1158/1078-0432.CCR-06-1516.
11. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990; 46(1):33-48. doi: 10.2307/2531628.
12. Braun TM. The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Control Clin Trials. 2002; 23(3):240-56. doi: 10.1016/S0197-2456(01)00205-7.
13. Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med. 2006; 25(14):2365-383. doi: 10.1002/sim.2325.
14. Wages NA, Tait C. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents,. J Biopharm Stat. 2015; 25(5):903-20. doi: 10.1080/10543406.2014.920873.
15. Wang M, Day R. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity,. J Biopharm Stat. 2010; 20(1):125-44. doi: 10.1080/10543400903280613.
16. Thall P, Cook J. Dose-Finding Based on Efficacy-Toxicity Trade-Offs. Biometrics. 2004; 60(3):684-93.
17. Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015; 2(9):367-75. doi: 10.1016/S2352-3026(15)00147-7.
18. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015; 29(9):1945-48. doi: 10.1038/leu.2015.54.
19. Chen TL, Estey EH, Othus M, Gardner KM, Markle LJ, Walter RB. Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study. Leuk Lymphoma. 2013; 54(11):2534-6. doi: 10.3109/10428194.2013.777836.
20. Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013; 13(1):263. doi: 10.1186/1471-2407-13-263.
21. Thall PF. Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials. Stat Sci. 2010; 25(2):227-44. doi: 10.1214/09-STS315.Bayesian.
22. Thall P, Herrick R, Nguyen H, Venier J, Norris J. Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials. 2014; 11(6):657-66. doi: 10.1177/1740774514547397.
23. Thall P, Cook J, Estey E. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations,. J Biopharm Stat. 2006; 16(5):623-38. doi: 10.1080/10543400600860394.
24. Cook JD. Efficacy-Toxicity trade-offs based on L-p norms: Technical Report UTMDABTR-003-06. Technical report. 2006.
25. Yuan Y, Nguyen HQ, Thall PF. Bayesian Designs for Phase I-II Clinical Trials, 1st edn. Boca Raton: CRC Press; 2016.
26. Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. J Am Stat Assoc. 2014; 109(506):525-36. doi: 10.1080/01621459.2014.881740.
27. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Kanfer E, Goldman JM, Olavarria E. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. 2012; 99(7):2304-9. doi: 10.1182/blood.V99.7.2304.
28. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19):1783-96. doi: 10.1056/NEJMoa1306494.
29. R Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/.
30. Soetaert K, Herman PMJ. A Practical Guide to Ecological Modelling. Using R as a Simulation Platform. Berlin: Springer; 2009, p. 372.
31. Yap C, Billingham L, Craddock C, O'Quigley J. Dose transition pathways: a design, analysis and operational tool for dose-finding trials using model-based designs. Trials. 2015; 16(S2):13. doi: 10.1186/1745-6215-16-S2-O13.
32. Thall PF, Nguyen HQ, Zinner RG. Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes. J R Stat Soc Series C: Appl Stat. 2017; 66(1):201-24. doi: 10.1111/rssc.12162.
33. Monahan J, Genz A. Spherical-Radial Integration Rules for Bayesian Computation. J Am Stat Assoc. 1997; 92(438):664-74.
34. Brock K. clintrials v0.1.4. GitHub, Zenodo. 2016. doi: 10.5281/zenodo.164621, https://zenodo.org/record/164621, https://github.com/brockk/clintrials.
35. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase i cancer clinical trials. J Natl Cancer Inst. 2009; 101(10):708-20. doi: 10.1093/jnci/djp079.